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The Ras-Byr2RBD Complex: Structural Basis for
Ras Effector Recognition in Yeast
system like yeast, which is in contrast to other small
GTPase families. The extra helical segment might be
involved in kinase activation.
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Abt. Strukturelle Biologie Introduction
Otto-Hahn-Str. 11
44227 Dortmund Ras proteins are key elements in intracellular signaling
Germany and are involved in a variety of vital processes such as
2 Max-Planck-Institut fu¨r medizinische Forschung DNA transcription, growth control, and differentiation.
Abt. Biophysik They function like molecular switches cycling between
Jahnstr. 29 GTP bound “on” and GDP bound “off” states [1, 2]. The
69120 Heidelberg biological activity of Ras is controlled by at least two
Germany kinds of regulators: guanine nucleotide exchange fac-
3 European Molecular Biology Laboratory tors (GEFs) that increase the nucleotide dissociation
Structural and Computational Biology Programme rate to facilitate binding of cellular abundant GTP and
Meyerhofstr. 1 GTPase activating proteins (GAPs) that accelerate the
69117 Heidelberg rate of GTP hydrolysis to return Ras to the inactive GDP
Germany bound form [3, 4]. Two regions, termed switch I and
4 Cold Spring Harbor Laboratory switch II, have been identified as major segments that
Cold Spring Harbor, New York 11724 define the conformational differences between active
and inactive Ras [5]. When bound to GTP, Ras is able
to interact with effector proteins to trigger a variety of
Summary cellular responses. At least three effectors have been
identified in mammalian cells: Raf kinase, PI(3) kinase,
Background: The small GTP binding protein Ras has and RalGDS [6]. A common feature of these is the Ras
important roles in cellular growth and differentiation. binding domain that, despite absence of sequence simi-
Mutant Ras is permanently active and contributes to larity, shares the ubiquitin fold as a common structural
cancer development. In its activated form, Ras interacts motif [7–12]. Structural work has so far characterized
with effector proteins, frequently initiating a kinase cas- Ras effector binding as the formation of an interprotein
cade. In the lower eukaryotic Schizosaccharomyces  sheet that is stabilized mainly by polar interactions
pombe, Byr2 kinase represents a Ras target that in terms between the switch I region of Ras and the N-terminal
of signal-transduction hierarchy can be considered a  strands of RBD including a midhelix [13–17].
homolog of mammalian Raf-kinase. The activation Byr2 is a Ser/Thr-specific protein kinase acting as
mechanism of protein kinases by Ras is not understood, mediator of signals for sexual differentiation in Schizo-
and there is no detailed structural information about Ras saccharomyces pombe by initiating a MAPK module,
binding domains (RBDs) in nonmammalian organisms. which is a highly conserved element in eukaryotes [18–
20]. It is a homolog of mammalian MEKK, and both are
Results: The crystal structure of the Ras-Byr2RBD at the same hierarchic level as Raf in the respective
complex at 3 A˚ resolution shows a complex architecture MAPK module, i.e., they are activated through interac-
similar to that observed in mammalian homologous sys- tion with Ras. It was demonstrated earlier that the Ras
tems, with an interprotein  sheet stabilized by predomi- binding domain (RBD) of Byr2 is necessary and sufficient
nantly polar interactions between the interacting com- for the protein to be translocated by Ras to the plasma
ponents. The C-terminal half of the Ras switch I region membrane [21]. The RBD of Byr2 is located in the regula-
contains most of the contact anchors, while on the Byr2
tory half of the protein at the amino terminus [22]. This
side, a number of residues from topologically distinct
RBD was isolated as a protein fragment comprising resi-
regions are involved in complex stabilization. A C-termi-
dues 65–180 or an N-terminally shorter version (residuesnal helical segment, which is not present in the known
71–180). As a first example of a Ras-effector complexmammalian homologous systems and which is part of
from nonmammalian organisms, we have characterizedthe auto-inhibitory region, has an additional binding site
the interaction between Ras and Byr2RBD by biochemi-outside the switch I region.
cal methods and have determined the three-dimensional
structure of the complex of the two proteins by X-ray
Conclusions: The structure of the Ras-Byr2 complex
crystallography.
confirms the Ras binding module as a communication
element mediating Ras-effector interactions; the Ras-
Byr2 complex is also conserved in a lower eukaryotic
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range as it does for the longer version. A summary ofTable 1. Summary of Crystallographic Analysis
the crystallographic data analysis is given in Table 1.
Data Collection
The structure of the Ras-Byr2RBD complex (Figure
Resolution (A˚) 3.0 1a) reveals Byr2RBD to have essentially the ubiquitin
Highest shell 3.1–3.0 fold as observed for the RBDs of Raf-kinase [8, 9],
Number of observations 109,981 (2,634)
RalGDS [7, 12], Rlf [10], Rgl [23], and PI(3) kinase [11],Number of unique reflections 8,526 (788)
consistent with the recent NMR assignment [24]. ACompleteness (%) 99.7 (100)
mixed five-stranded  sheet is flanked by at least twoRsymm (%)a 13.9 (30.5)
l/ 18.6 (4.1) helical segments (see below), one of which seems to be
flexible in our crystals. An additional helix (3) was foundRefinement
at the C-terminal end of Byr2RBD with no counterpart
Resolution range (A˚) 25–3
in either of the RBDs known so far. A structure-basedNumber of reflections 8526
sequence alignment is shown in Figure 1b. As mentionedRwork (%)b 23.6
Rfree (%)c 31.2 above, the segment covering residues 127–139 is not
Rmsd bonds (A˚) 0.008 ordered in the crystal, but electron density suggests
Rmsd angles (deg) 1.375 some helical contents. Comparison with the NMR model
(see Gronwald et al. [74] in this issue) confirms the basicNumbers in parentheses refer to highest resolution shell.




| Ihi  Ih | / 
hi
Ihi, where Ihi is the scaled intensity of the fold, particularly in defining the second  helix (2) in
solution.i th symmetry related observation of reflection h and Ih is the mean
value.
b Rwork  
h
| Foh  Fch | / 
h
Foh, where Foh and Fch are the observed The Complex Interface
and calculated structure factor amplitudes for reflection h. The complex shows a similar protein-protein interaction
c R factor calculated for 10% randomly chosen reflections not in- pattern as that seen in previously solved Ras effector
cluded in the refinement. complex structures with an interprotein  sheet as the
most apparent feature (Figure 1a). It buries about 1200 A˚2
of solvent-accessible surface area in its interface, similar
to the other known Ras complexes with Raf [13, 14],Results and Discussion
RalGDS [15, 16], and PI(3) kinase [17]. The switch regions
I and II of Ras, which have been defined as proteinStructure of Byr2RBD
The complex between Byr2RBD (71–180) and GppNHp segments that change their conformation upon transi-
tion between GTP and GDP bound forms [5], are in thebound H-Ras (1–166) was purified and crystallized, and
the structure was determined at 3 A˚ resolution, as de- canonical GTP bound conformation [25]. In particular,
Tyr32 from switch I is closing upon the phosphate bind-scribed in the Experimental Procedures. The current
model covers the full H-Ras molecule and Byr2 residues ing region and interacts with the -phosphate. The situa-
tion is consistent with the guanine nucleotide dissocia-71–165; a middle segment of residues 127–139 and the
end residues 166–180 were ill defined in the electron tion inhibitory (GDI) effect resulting from interaction of
RBDs with Ras, as observed earlier [26]. Since mamma-density. Although a shorter construct of Byr2RBD (resi-
dues 71–171) in complex with Ras has improved crystal- lian Ras and Ras1 from S. pombe are highly homologous
and the interacting residues are totally conserved, welization properties, the resolution remains in the same
Figure 1. The Ras-Byr2RBD Complex
(a) Ribbon representation showing Byr2RBD on the left and Ras on the right. Switch I is shown in light blue, switch II is in dark blue, and the
nucleotide is in pink. The presumed helical segment in the middle of the RBD is indicated as a dashed wavy line.
(b) Structure-based sequence alignment of the RBDs from Raf [13], PI3-kinase [17], RalGDS [7], and Byr2 (this work), done with the program
STAMP [72]. Assignment of secondary structure elements according to the program DSSP [73] is included for Byr2RBD; dashed lines indicate
disordered regions. Structurally related regions are boxed and residues conserved as hydrophobic or polar amino acids are in yellow and
red, respectively. Residues involved in the interaction with Ras are marked with green dots.
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Figure 2. View of the Complex Interface
(a) Close-up view of the complex interface with selected side chains involved in interprotein interactions included.
(b) Cartoon of the complex interface indicating favorable interactions (red lines) inferred from the structural model. Arrow heads indicate side
chain, and straight ends indicate main chain contribution to the respective interactions.
can assume that the present structure is a very close the carbonyl oxygen of Ser39. Arg74Byr in strand1 forms
a salt bridge with the carboxylate group of Glu37. Thehomolog of the real S. pombe complex.
As far as the definition of interactions is possible given side chain of Lys101Byr at the C-terminal end of helix 1
is in an orientation where a salt bridge may be formedthe limited resolution, polar contacts seem to play a
major role in the complex stabilization (Figure 2a). A with Asp33 or Asp38. This situation is reminiscent of the
Ras-RasGAP complex where a conserved lysine (Lys949schematic view of the interface is given in Figure 2b. As
observed in mammalian Ras effector complexes, similar of p120GAP) interacts with these two residues in a simi-
lar geometry [28]. The Byr2 mutant K101E was reportedresidues on the Ras side are involved in complex forma-
tion. These polar interactions involve residues almost to disrupt interaction between Ras and Byr2 [22]. Finally,
a contact conceivable from the C-terminal  helix ofexclusively from switch I, particularly Asp33, Glu37,
Asp38, Ser39, and Arg41; these same residues are also Byr2RBD to the G domain core of Ras.
involved in the interaction with the Raf kinase [13, 14]
and PI(3)kinase [17], whereas the RalGDS complex does Mutational Analysis of the Interface
In order to analyze the contribution of individual residuesnot use Ser39 or Arg41 [15, 16]. As in the Raf kinase
and RalGDS complex, no residues from switch II are participating in intermolecular interactions, we have car-
ried out site-directed mutagenesis studies. The interac-employed for the interaction, in contrast with the com-
plex with PI(3)kinase where Ras also uses residues from tion between Ras and Byr2RBD (65–180) was quantified
by the GDI method as described earlier for other Rasswitch II, presumably for allosterically regulating the ki-
nase [17]. Strikingly, Asp30 and Glu31, residues that effectors like the RBDs of Raf, RalGDS, and AF6 [27,
29]. On the Ras side, we selected for substitution thosedetermine target specificities of Rap and Ras toward
the RBDs of Raf and RalGDS, respectively [14, 27], do residues that comprise the classical effector region (res-
idues 32–40) as well as residues flanking this region onnot show contacts with Byr2RBD (see below).
On the Byr2 side, most of the residues participating both sides. We prepared a number of mutants that have
been used as partial loss-of-function in mammalian cellin intermolecular interactions are located in strand 2
(Figures 1b and 2a), representing the edge of the protein culture studies and/or have been studied extensively
for interaction with different effectors. These mutationsthat is directed toward Ras. They are primarily polar in
character, and they mainly contact amino acids in the are supposed to weaken the interaction with some ef-
fectors and leave it intact with others [30–38]. On thestretch from residue 38 to 41 of Ras. The guanidinium
group of Arg83Byr is in close proximity of the effector Byr2 side, residues were selected on the basis of the
observed contacts in the present structure of the Ras-loop main chain region, allowing a polar contact with
Structure
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[6, 40]. As discussed above, Asp33 and Asp38 are both
potential salt-bridging partners for Lys101Byr, located on
the C-terminal end of helix 1 in the RBD. Irrespective
of the possible number of interactions (arrows in Figure
2b), the side chain of Ser39 seems to provide no contri-
bution for Byr2 binding, since the alanine mutation in-
creases the Kd value only 3-fold. The contribution of the
main chain contacts emanating from Ser39 (Figure 2b)
are not accessible by mutational analysis. Thr35 is a
residue totally conserved in all GTP binding proteins
and is involved in the switch mechanism by virtue of
being bound to the -phosphate [41]. The T35S mutant,
which has been used as a partial loss-of-function muta-
tion specific for the Ras pathway, is nevertheless com-
promised in its ability to interact with all effectors, even
though it is not involved in any direct interaction. Simi-
larly, in the Ras-Byr2RBD complex, Thr35 is not in direct
contact, but the T35S mutation increases the Kd 12-fold,
most likely due to a change in the dynamic properties
of Ras [42].
The second category is residues flanking the effector
region. As mentioned above, determinants of Ras/Rap
effector specificity toward Raf and RalGDS turned out
not to be involved in the binding to Byr2RBD. Mutation
of Ras residues Asp30 and Glu31 to the corresponding
residues in Rap proteins, Glu and Lys, results in only a
2-fold increase of the Kd value. This is consistent with
the observation that these residues are not contributing
to the complex interface in our structure. In contrast,
Figure 3. Mutational Analysis Arg 41, which is highly conserved within the Ras subfam-
Kd values (M) for the Ras-Byr2 interaction as determined by the ily, has a modest contribution to the interaction with
GDI assay at 37	C. The experimental error on the Kd values is 20%. Byr2, with a 7-fold reduction of affinity observed for the
The values of 100 M represent the lower estimates for each of the R41A mutant.
two mutants. The third category is partial loss of function mutants.
The E37G mutation was one of the first partial loss of
Byr2RBD complex. The results for the Ras and the Byr2 function mutants discovered, which established the
mutants are represented in Figure 3. No difference in concept that Ras uses multiple pathways for cell trans-
Ras binding affinity was observed between the 65–171 formation. It was found in a two-hybrid screen as a
and the 65–180 constructs (data not shown). The results mutant that fails to interact with Raf but is unimpaired
will be discussed in the context of the structural findings. for Byr2 binding [30]. Since the mutation has only a minor
The effects of Ras mutations may be grouped into effect on the interaction, the salt bridge with Arg74Byr
four categories. First, in the classical effector region, is probably less important. Other commonly employed
three residues play an important role for the interaction mutations of that category include Y40C and D38E,
with Byr2, i.e., Asp33, Asp38, and Tyr40. When Asp33 which show rather large effects on binding. Both heavily
and Asp38 are mutated to Ala, a greater than 10-fold interfere with the Byr2RBD interaction to an extent that
increase of the Kd value is observed for each. The same their affinity cannot be measured with the GDI technique.
is true for Y40F, which is somewhat surprising since the Although Asp38 is also involved in the Ras-Raf interac-
hydroxyl group is not likely to form polar contacts within tion, the D38E mutation has only a small effect on that
the interface. In the case of Asp38, it is interesting to interaction. This highlights the notion that the analysis
note that on the one hand a longer side chain is not of a protein-protein interface by a three-dimensional
tolerated, since D38E has an even much more pro- structure does not per se indicate the importance of
nounced effect on the binding affinity indicating repul- individual residues for the interaction and/or allow us
sive effects; and on the other hand, the negative charge to predict a priori the effect of a particular mutation.
seems to play a major role, since the D38N and D38A While the effect of Cys in position 40 can apparently not
mutants show a somewhat smaller effect with 25- and be rationalized from our structural model, the possible
18-fold reduction, respectively. The latter finding is contact between Asp38 and Lys101Byr makes a modest
quantitatively different from the 10-fold difference for contribution to the binding affinity (Figure 2a).
D38N and D38A found by Ohnishi et al. [39]. However, The fourth category is mutants in the switch II region.
considering that they used wild-type and mutant Ras The glutamate residues at positions 62 and 63 do not
peptides instead of the intact RBD, the results are re- participate in the Ras-Byr2RBD interaction, as indicated
markably consistent. The Asp38→Glu mutation has by only a 2-fold change in affinity for the Ala mutants.
been shown to have a major effect on Ras effector and This is not unexpected, as these residues are solvent
Ras-RasGAP interactions, underscoring the importance exposed and are not involved in the interaction with the
Byr2RBD. The same was observed for the interactionof Asp38 for the interaction with effectors and regulators
Crystal Structure of Ras-Byr2RBD Complex
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between Ras and RalGDS [16], although crystal contacts Binding, in turn, induces activation of kinases, as dem-
onstrated in vitro and in vivo for PAK [54, 55] and Rhowith a symmetry-related molecule via these residues
had been suggested to contribute to the interaction [7]. kinases [56, 57]. Activation, in addition to translocation,
is also discussed for the interaction between Ras andThe decreased binding affinity of the D57A mutant can
be explained by altered Mg2
 coordination, which has Raf [58, 59], although structural models for such a mech-
anism do not exist. For PAK it has been shown thatan effect on nucleotide binding and thereby on Byr2
interaction. the N-terminal regulatory domain binds directly to and
thereby inhibits the catalytic domain [60, 61], and struc-On the Byr2RBD side, there are two residues contrib-
uting strongly to the interaction; their mutation to Ala tural studies on a complex between the regulatory and
the catalytic domain on one side [62] and on the complexleads to a 100-fold decrease in affinity. One of these is
Lys101Byr which was discovered earlier in a screen for between Cdc42-GTP and a regulatory fragment on the
other side [51, 63] have suggested how the binding ofRas/Byr2 disruptive mutants [22] and is close enough
to both Asp33 and Asp38 for salt bridges. A similar the G protein induces a large conformational change
which relieves the inhibition of the catalytic domain.crucial salt bridge is described for Arg89 from c-Raf,
which is located in the center of the Ras-Raf interface A similar interaction has been demonstrated for Byr2,
where a detailed mapping of the protein has identified[13, 14] and has also been found in a genetic screen of
the Drosophila sevenless pathway [43]. A similar large an RBD, residues 71–180, and a domain that binds the
catalytic domain (CBD), residues 151–260 [22]. Thesecontribution to the binding energy is due to Arg83Byr,
whereas mutation of Gln81Byr reduces the affinity a mod- authors have also shown that these two domains overlap
considerably. In the present structure we have used anerate 20-fold. Given the mutual stabilization of Arg83Byr
and Gln81Byr (Figure 2), the observed effects on binding RBD fragment that contains part of the CBD. Indeed,
the structure shows that the present construct containsaffinity may be strongly interdependent. Interestingly,
Arg160Byr from the C-terminal helix moderately contrib- an extra helix (3) that is not present in either RafRBD
or RalGDS-RBD. This helix is close to Ras and actuallyutes to binding and is in the structure in proximity to
Asp54 of Ras. Overall, the interaction between Ras and is involved in the interface by forming an interaction
between Arg160Byr and Asp54 in  strand 3 of Ras; thereByr2 is dominated by charge-charge interactions, where
Byr2RBD is primarily positively charged. This was also are even more potentially interacting pairs of residues
in this area of the interface. The 10-fold increase ofobserved for Raf, RalGDS, and PI(3)K [14–17], and it
appears to be a common feature for Ras effectors to the Kd value after mutation of Arg160Byr supports the
observation that the additional helix 3 contributes tobe a complement to the negative surface potential of
Ras in the effector region. the interaction with Ras. It could thus easily be envi-
sioned that the binding of Ras•GTP to the RBD induces a
structural change in the CBD that releases the inhibitoryConcluding Remarks
interaction with the catalytic domain and thus leads toBased on the primary sequence, it seems difficult to
activation of the kinase activity of Byr2. Obviously thispredict Ras effectors or at least their RBDs. Some of
model has to be verified by further structural studies onthe RBDs or Ras-associating (RA) domains predicted
larger fragments of Byr2, which include the completedo not show any interaction with Ras, e.g., the uncon-
CBD and the kinase domain.
ventional myosin and Rho-GAP myr5 [44, 45]. On the
Is the envisioned activation mechanism unique for
other hand, there are a number of RBDs that do not
nonmammalian Ras effectors or would there be implica-
show up in the database search like the RBDs of Raf and
tions for other effector interaction? Raf kinase contains,
Byr2. Nevertheless, Ras-effector interaction has been
in addition to the RBD, a cysteine-rich domain (CRD).
demonstrated to show a high level of structural conser-
This CRD is directly C-terminal to the RBD, and it has
vation. This reiterates earlier observations that different been shown that while the interaction of Ras with RBD
effectors of Ras, now including the effector Byr2 of Ras1 is necessary for the translocation of Raf to the plasma
in the yeast S. pombe, have no recognizable sequence membrane, the interaction with CRD is believed to be
conservation but yet show the same three-dimensional crucial for the activation of the kinase (see [64]). It has
structure and the very stable ubiquitin superfold [46] and further been shown that residues near switch II or near
also react with Ras (Ras1) in the same basic interaction residue 45 are involved in the interaction with the CRD
pattern by forming an interprotein  sheet. During com- [65, 66]. In the analogy to Byr2, one could imagine that
plex formation, there is no appreciable conformational Ras binds to Raf in a bipartite interaction mode similar
change involving the effector [7, 8, 11–17]. This is in to what we find for Ras-Byr2, with the second site being
contrast to members of the Rho family, where the ef- involved in activation. Confirmation for such a scenario
fectors of Rac and Cdc42 contain a region with con- comes from the structure of the Ras-PI(3)K complex,
served sequence homology, the CRIB or GBD region where Ras uses the conventional RBD for a canonical
[47, 48], which does not form a stable fold [49–53]. Here, interprotein  sheet interaction. In addition, it interacts
complex formation with the GTP binding protein in- with the catalytic part of the kinase via the switch II
volves a large conformational change. region, and it is believed that this interaction induces the
well-documented activation of the kinase activity [17].
Biological Implications
Experimental Procedures
A number of kinases are effectors of GTP binding pro- Protein Purification and Characterization
teins of the Rho and Ras subfamily in that the binding H-Ras (1–166) was synthesized in Escherichia coli and purified from
the cleared cell lysate by ion exchange chromatography followed byis dependent on the triphosphate conformation [6].
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size exclusion chromatography, as reported earlier [67]. Exchange of In alternate rounds of interactive model building (program O, [70])
and refinement (program CNS, [71]), with the RafRBD model [13] as athe bound GDP for the nonhydrolyzable GTP analog GppNHp or
the fluorescent mant-analog thereof is described in [27]. The Ras guide, the Byr2RBD component was completed to residues 71–165,
with the exception of the presumably helical segment of residuesbinding domain of Byr2 kinase (Byr2RBD) was cloned in a pGEX-
2T plasmid leading to the synthesis of the glutathione S-transferase 127–139, which showed only poor electron density. The NMR model
(see Gronwald et al. [74] in the accompanying paper) confirms thefusion protein in Escherichia coli strain BL21. After purification, ac-
cording to standard protocols and cleavage of the fusion protein helical contents of the segment (see the structure description). A
number of side chains did not show reasonable electron densitywith thrombin, the Byr2RBD fragment was subjected to size-exclu-
sion chromatography (Superdex-75, Pharmacia). A dimer and a mo- and were therefore modeled stereochemically. These include Arg98,
Gln92, Lys93, Glu105, Lys109, Gln116, Ser117/118, Arg119, Glu126,nomer fraction of similar sizes were eluted from the column; both
were stable as such. Also for Byr2RBD in complex with Ras, dimer Arg140, and Phe155 in Byr2RBD. Structure visualization was done
with the programs MOLSCRIPT [75] and Raster 3D [76].and monomer fractions were collected from the size exclusion col-
umn. The proteins were concentrated to 20–25 mg/ml by using
centrifugal concentrators (VivaScience) and were stored at 80	C Acknowledgments
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